Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT00243386
First received: October 21, 2005
Last updated: October 19, 2012
Last verified: October 2012
  Purpose

The primary purpose of this randomized, two-arm parallel clinical study in 66 previously treated patients with severe or moderately severe hemophilia A is to compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours; actual dose determined by the investigator) with that of alternate prophylaxis (20-80 IU/kg every 72 + 6 hours; actual dose determined by Baxter utilizing an algorithm and the patient's pharmacokinetic data). The rates of bleeding episodes for the on-demand regimen and the prophylaxis regimens will also be compared for the cross-over portion of the study. Enrolled patients will be treated originally on demand for a period of 6 months and then they will be randomized into one of the prophylaxis arms. Prophylactic treatment will last for a period of 12 months +/- 2 weeks.


Condition Intervention Phase
Hemophilia A
Drug: Antihemophilic factor, recombinant, manufactured protein-free
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A

Resource links provided by NLM:


Further study details as provided by Baxter Healthcare Corporation:

Primary Outcome Measures:
  • Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens [ Time Frame: 12 months ±2 weeks ] [ Designated as safety issue: No ]

    Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Study Part 2):

    1. Standard prophylaxis (20-40 IU/kg (every 48 ±6 hour), exact regimen determined by investigator)
    2. PK-driven prophylaxis (20-80 IU/kg (every 72 ±6 hour), exact regimen determined by sponsor)

    Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X = bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.


  • Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens [ Time Frame: 12 months ±2 weeks ] [ Designated as safety issue: No ]

    Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study):

    1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg.
    2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.


Secondary Outcome Measures:
  • Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens [ Time Frame: On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks) ] [ Designated as safety issue: No ]

    Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.

    Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Standard Prophylaxis Treatment TABR).

    Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).


  • Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens [ Time Frame: On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks) ] [ Designated as safety issue: No ]

    Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.

    Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (PK-Driven Prophylaxis Treatment TABR)

    Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).


  • Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens [ Time Frame: On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks) ] [ Designated as safety issue: No ]

    Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.

    Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Any Prophylaxis Treatment TABR).

    Any Prophylaxis = Standard or PK-Driven Prophylaxis

    Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).


  • Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm [ Time Frame: 12 months ±2 weeks ] [ Designated as safety issue: No ]

    Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study):

    1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg.
    2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.

  • Bleeding Episodes Treated With 1 to ≥4 Infusions [ Time Frame: Throughout the study period (4 years and 5 months) ] [ Designated as safety issue: No ]
    The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis

  • Assessment of Hemostasis for Treatment of Bleeding Episodes [ Time Frame: On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks) ] [ Designated as safety issue: No ]

    Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):

    Excellent: Full pain relief & bleeding cessation within ~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis;

    Good: Definite pain relief and/or improvement in bleeding within ~8 hrs after infusion. Possibly requires >1 infusion for complete resolution;

    Fair: Probable or slight relief of pain & slight improvement in bleeding within

    ~8 hrs after infusion. Requires >1 infusion for complete resolution;

    None: No improvement or condition worsens


  • Total Area Under the Curve (AUC) [ Time Frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion ] [ Designated as safety issue: No ]
    Total AUC estimated by AUC 0-48h plus an area extrapolated from the log-linear regression model

  • Area Under the Curve [ Time Frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion ] [ Designated as safety issue: No ]
    Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method

  • Maximum Plasma Concentration (C-max) [ Time Frame: Within 1 hour post-infusion ] [ Designated as safety issue: No ]
    Maximal Factor VIII Concentration After Infusion

  • Adjusted Incremental Recovery (IR) [ Time Frame: 30 minutes pre-infusion to 48 hours post-infusion ] [ Designated as safety issue: No ]

    Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits.

    Adjusted IR defined as:

    [Cmax (IU/dL) - pre-infusion FVIII (IU/dL)]/dose (IU/kg)


  • Terminal Half-life [ Time Frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion ] [ Designated as safety issue: No ]
    Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.

  • Weight-Adjusted Clearance [ Time Frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion ] [ Designated as safety issue: No ]
    Computed as the weight-adjusted dose divided by total AUC

  • Mean Residence Time [ Time Frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion ] [ Designated as safety issue: No ]
    Computed as total Area Under the Moment Curve (AUMC) divided by the total AUC

  • Volume of Distribution at Steady State [ Time Frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion ] [ Designated as safety issue: No ]
    Computed as weight-adjusted clearance * mean residence time

  • Factor VIII Inhibitor Development [ Time Frame: Throughout study period (4 years and 5 months) ] [ Designated as safety issue: Yes ]
    Number of treated participants who developed factor VIII inhibitors

  • Number of Participants With AEs Related to Investigational Product (IP) [ Time Frame: Throughout study period (4 years and 5 months) ] [ Designated as safety issue: Yes ]
    Number of treated participants with AEs judged to be possibly or probably related to treatment with IP

  • Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP) [ Time Frame: Throughout study period (4 years and 5 months) ] [ Designated as safety issue: Yes ]
    Number of treated participants with 1 or more AE regardless of relatedness to IP

  • Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen [ Time Frame: Throughout the study period (4 years and 5 months) ] [ Designated as safety issue: Yes ]
  • Number of Participants With SAEs by Preferred MedDRA Term and Treatment Regimen [ Time Frame: Throughout the study period (4 years and 5 months) ] [ Designated as safety issue: Yes ]
  • AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness [ Time Frame: Throughout study period (4 years and 5 months) ] [ Designated as safety issue: Yes ]
  • Number of Participants With Severe SAEs and Severe Non-SAEs by Preferred MedDRA Term and Treatment Regimen [ Time Frame: Throughout the study period (4 years and 5 months) ] [ Designated as safety issue: Yes ]
    This outcome is focused only on SEVERE SAEs and SEVERE non-SAEs

  • Baseline Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS at the End of Treatment Regimens [ Time Frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months) ] [ Designated as safety issue: No ]
    Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • HRQoL Scores Change From On-Demand Treatment Regimen Period Through Prophylaxis Period [ Time Frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months) ] [ Designated as safety issue: No ]

    Differences in health domain scores = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen

    Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS).

    Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.


  • Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period [ Time Frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months) ] [ Designated as safety issue: No ]

    Change = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen.

    Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.


  • Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period [ Time Frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months) ] [ Designated as safety issue: No ]

    Change = (End of on-demand treatment) - (End of prophylaxis regimen) A negative value for the median difference equates to a larger domain score for the prophylaxis regimen.

    Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.



Enrollment: 82
Study Start Date: January 2006
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Standard prophylaxis
Drug: Antihemophilic factor, recombinant, manufactured protein-free
Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
Experimental: 2
PK-driven prophylaxis
Drug: Antihemophilic factor, recombinant, manufactured protein-free
PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data

  Eligibility

Ages Eligible for Study:   7 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level <= 2% of normal, as tested at screening
  • The subject has a documented history of at least 150 exposure days to factor VIII concentrates (either plasma-derived or recombinant)
  • The subject is within 7 to 65 years of age
  • The subject has a Karnofsky performance score > (greater than) 60
  • The subject is human immunodeficiency virus negative (HIV-) or is HIV+ with a CD4 count >= 400 cells/mm³ (CD4 count determined at screening, if necessary)
  • The subject has been on a documented on-demand treatment regimen for at least 12 months immediately prior to enrollment
  • The subject has a documented history (e.g. in medical charts or dispensing information, or signed investigator statement) of at least 8 joint hemorrhages in the 12 months immediately prior to enrollment
  • The subject resides within the coverage area of the mobile compliance device; coverage area will be determined at screening
  • The subject or the subject's legally authorized representative has provided written informed consent

Exclusion Criteria:

  • The subject has a known hypersensitivity to factor VIII concentrates or mouse or hamster proteins
  • The subject has a history of factor VIII inhibitors with a titer >= 0.6 BU (by Bethesda or Nijmegen assay) at any time prior to screening
  • The subject has a detectable factor VIII inhibitor at screening, with a titer >= 0.4 BU (by Nijmegen Assay) in the central laboratory
  • The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
  • The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative platelet defect or von Willebrand's Disease)
  • The subject has been treated during the last sixty (60) days prior to or is being treated at screening/enrollment with an immunomodulating drug.
  • The subject has participated in another investigational study within thirty (30) days of enrollment
  • The subject has previously participated in a clinical study with rAHF-PFM
  • The subject's clinical condition may require a major surgery (defined as moderate to critical risk and perioperative blood loss ≥ 500 mL) during the period of the subject's participation in the study
  • The subject is female of childbearing potential with a positive pregnancy test
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00243386

  Show 29 Study Locations
Sponsors and Collaborators
Baxter Healthcare Corporation
Investigators
Principal Investigator: Peter Collins, MD Cardiff and Vale NHS
  More Information

No publications provided by Baxter Healthcare Corporation

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT00243386     History of Changes
Other Study ID Numbers: 060201
Study First Received: October 21, 2005
Results First Received: March 14, 2012
Last Updated: October 19, 2012
Health Authority: United States: Food and Drug Administration
Austria: Federal Ministry for Health and Women
Czech Republic: State Institute for Drug Control
Greece: Ministry of Health and Welfare
Hungary: National Institute of Pharmacy
Italy: Ministry of Health
Slovenia: Agency for Medicinal Products - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Poland: Ministry of Health
Russia: Ministry of Health of the Russian Federation

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Coagulation Protein Disorders
Genetic Diseases, Inborn
Hematologic Diseases
Hemorrhagic Disorders
Factor VIII
Coagulants
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014